How Biotech Startups Are Using RNA Editing Beyond CRISPR

In this episode of Biotech Business with Fexingo, Lucas and Luna explore the emerging field of RNA editing as a therapeutic tool, focusing on how startups like Wave Life Sciences and Ascidian Therapeutics are developing drugs that fix genetic mutations at the RNA level without altering DNA. Unlike CRISPR, which makes permanent changes, RNA editing offers a reversible and potentially safer approach for treating diseases like alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy. The hosts break down the key technology behind ADAR enzymes, the advantages over CRISPR, and the latest clinical data from 2026. They also discuss the business landscape: which companies are leading, how investors are viewing the space, and the regulatory hurdles ahead. If you work in biotech or just follow drug development, this episode gives you a concrete understanding of why RNA editing could be the next wave after CRISPR. #RNAEditing #Biotech #WaveLifeSciences #AscidianTherapeutics #ADAR #CRISPR #DrugDiscovery #GeneTherapy #Startups #Alpha1Antitrypsin #Duchenne #ClinicalTrials #FDA #Business #Technology #FexingoBusiness #BiotechPodcast #LifeSciences Keep every episode free: buymeacoffee.com/fexingo